Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

New York, New York-- (Newsfile Corp. - March 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial results ...

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical companies next week. CEO Lars Jørgensen told reporters Thursday ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet demand.

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock. A half-hearted rating from Morgan Stanley yesterday isn't cheering investors up very much at all. Yet a new study ...